TY - JOUR T1 - Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency JF - In Vivo JO - In Vivo SP - 2831 LP - 2840 DO - 10.21873/invivo.12570 VL - 35 IS - 5 AU - KOKI KATO AU - TOMOHIRO MIZUNO AU - TAKENAO KOSEKI AU - YOSHIMASA ITO AU - MASAKAZU HATANO AU - KAZUO TAKAHASHI AU - SHIGEKI YAMADA AU - NAOTAKE TSUBOI Y1 - 2021/09/01 UR - http://iv.iiarjournals.org/content/35/5/2831.abstract N2 - Background/Aim: Concomitant proton pump inhibitor (PPI) and immune checkpoint inhibitor (ICPI) were determined as risk factors of acute kidney injury. To identify the type of PPI associated with ICPI-induced nephritis, we used the Japanese Adverse Drug Event Report database. Patients and Methods: ICPIs (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, and avelumab) and PPIs (esomeprazole, omeprazole, vonoprazan, rabeprazole, and lansoprazole) were selected as suspected nephritis-inducing drugs. Results: The cases of concomitant use of atezolizumab and rabeprazole, ipilimumab and omeprazole, ipilimumab and lansoprazole, nivolumab and esomeprazole, nivolumab and omeprazole, nivolumab and rabeprazole, nivolumab and lansoprazole, pembrolizumab and esomeprazole, as well as pembrolizumab and lansoprazole had a significantly higher reported odds ratio than monotherapy cases. Conclusion: Male patients or patients using ICPIs and PPIs (excluded vonoprazan) concomitantly should be monitored for renal function after chemotherapy. ER -